Novo Nordisk Turns the Page: EU Backs Oral Wegovy as Liver Disease Data and a DKK 11.2bn Buyback Lif
Novo Nordisk launches DKK 11.2B buyback, receives EU approval for two new Wegovy formulations, posts strong oral tablet…
Novo Nordisk Secures Dual EU Backing for Wegovy as Semaglutide Liver Data Strengthens Pipeline
Novo Nordisk gains CHMP backing for Wegovy 7.2mg pen and oral tablet, presents promising MASH data, and announces…
Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide
Trial liver safety data from the ‘ESSENCE’ trial confirm semaglutide’s favourable hepatic profile in patients with Metabolic Dysfunction-associated…